about
Burden of diagnostic radiation exposure in children with sickle cell disease.Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell programChromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposureAutonomic nervous system reactivity: children with and without sickle cell disease.Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell DiseaseParental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseInactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.Emerging point-of-care technologies for sickle cell disease screening and monitoring.Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia.Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy.Increased left main coronary artery dimensions in children with sickle cell disease.Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
P2860
Q33560812-73073A76-B747-4882-A07B-C0C71BBAD572Q34964869-1767C2D3-E70A-4C8E-BBCC-0D4DC76D6478Q35036897-BA06CE25-6586-4671-951D-85770B00BF78Q35087447-A46D5736-68CB-455B-8BBC-7155E4E437BCQ35234959-6CEDBDEC-2013-4CEB-9EE8-4E11CC47CC8CQ36058141-9B7B4399-2DCA-4F51-90E2-9F68C571A182Q36763705-9D52F751-2AFF-4E79-B243-A429CC201561Q37008748-57924CD4-5624-4669-923C-B9080E836BF2Q38804432-F4092857-B0C2-4E15-8E20-897A8BD9B073Q39143787-33DA966B-4B16-4E42-9FA1-C8B00AD91042Q39412777-E7919C2E-B8AB-4484-8FFB-771BFC4ED3E4Q39442230-FA83FECE-E6CA-4EF7-976B-1BD4848F76D5Q40038732-14F286F4-67DC-4F28-928E-B6E7CCBDEA09Q44305564-ECDF1059-F231-436A-8340-66CAE13539B0Q48015152-9CA439C6-77A5-4CF2-8E33-E47D1D71B73DQ50866238-916D4E5A-A1F2-4793-AE47-64D1ECE5939B
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Hydroxyurea for children with sickle cell disease
@ast
Hydroxyurea for children with sickle cell disease
@en
type
label
Hydroxyurea for children with sickle cell disease
@ast
Hydroxyurea for children with sickle cell disease
@en
prefLabel
Hydroxyurea for children with sickle cell disease
@ast
Hydroxyurea for children with sickle cell disease
@en
P2860
P1476
Hydroxyurea for children with sickle cell disease
@en
P2093
Russell E Ware
P2860
P304
P356
10.1016/J.HOC.2009.11.002
P577
2010-02-01T00:00:00Z